ATE481089T1 - Orale formulierungen mit kontrollierter freisetzung eines interleukin-1-beta-converting- enzyme inhibitors - Google Patents

Orale formulierungen mit kontrollierter freisetzung eines interleukin-1-beta-converting- enzyme inhibitors

Info

Publication number
ATE481089T1
ATE481089T1 AT07795477T AT07795477T ATE481089T1 AT E481089 T1 ATE481089 T1 AT E481089T1 AT 07795477 T AT07795477 T AT 07795477T AT 07795477 T AT07795477 T AT 07795477T AT E481089 T1 ATE481089 T1 AT E481089T1
Authority
AT
Austria
Prior art keywords
interleukin
controlled release
beta
converting enzyme
enzyme inhibitor
Prior art date
Application number
AT07795477T
Other languages
English (en)
Inventor
Irina Kadiyala
Wu Lin
Patricia Hurter
Original Assignee
Vertex Pharma
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Vertex Pharma filed Critical Vertex Pharma
Application granted granted Critical
Publication of ATE481089T1 publication Critical patent/ATE481089T1/de

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A61K9/16—Agglomerates; Granulates; Microbeadlets ; Microspheres; Pellets; Solid products obtained by spray drying, spray freeze drying, spray congealing,(multiple) emulsion solvent evaporation or extraction
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A61K9/16—Agglomerates; Granulates; Microbeadlets ; Microspheres; Pellets; Solid products obtained by spray drying, spray freeze drying, spray congealing,(multiple) emulsion solvent evaporation or extraction
    • A61K9/1682—Processes
    • A61K9/1688—Processes resulting in pure drug agglomerate optionally containing up to 5% of excipient
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/335—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
    • A61K31/34—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having five-membered rings with one oxygen as the only ring hetero atom, e.g. isosorbide
    • A61K31/341—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having five-membered rings with one oxygen as the only ring hetero atom, e.g. isosorbide not condensed with another ring, e.g. ranitidine, furosemide, bufetolol, muscarine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/40—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
    • A61K31/401—Proline; Derivatives thereof, e.g. captopril
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2072—Pills, tablets, discs, rods characterised by shape, structure or size; Tablets with holes, special break lines or identification marks; Partially coated tablets; Disintegrating flat shaped forms
    • A61K9/2077—Tablets comprising drug-containing microparticles in a substantial amount of supporting matrix; Multiparticulate tablets
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2095—Tabletting processes
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/06—Antipsoriatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]

Landscapes

  • Health & Medical Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Epidemiology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Rheumatology (AREA)
  • Dermatology (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Immunology (AREA)
  • Pain & Pain Management (AREA)
  • Medicinal Preparation (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Agricultural Chemicals And Associated Chemicals (AREA)
  • Medical Preparation Storing Or Oral Administration Devices (AREA)
AT07795477T 2006-05-31 2007-05-30 Orale formulierungen mit kontrollierter freisetzung eines interleukin-1-beta-converting- enzyme inhibitors ATE481089T1 (de)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US80977906P 2006-05-31 2006-05-31
PCT/US2007/012715 WO2007142951A2 (en) 2006-05-31 2007-05-30 Oral controlled release formulations of an interleukin-1 beta converting enzyme inihibitor

Publications (1)

Publication Number Publication Date
ATE481089T1 true ATE481089T1 (de) 2010-10-15

Family

ID=38802004

Family Applications (1)

Application Number Title Priority Date Filing Date
AT07795477T ATE481089T1 (de) 2006-05-31 2007-05-30 Orale formulierungen mit kontrollierter freisetzung eines interleukin-1-beta-converting- enzyme inhibitors

Country Status (19)

Country Link
US (2) US20080070972A1 (de)
EP (1) EP2037887B1 (de)
JP (1) JP2009538912A (de)
KR (1) KR20090018843A (de)
CN (1) CN101489530A (de)
AT (1) ATE481089T1 (de)
AU (1) AU2007254990A1 (de)
CA (1) CA2653625A1 (de)
CY (1) CY1111439T1 (de)
DE (1) DE602007009230D1 (de)
DK (1) DK2037887T3 (de)
ES (1) ES2351947T3 (de)
IL (1) IL195572A (de)
MX (1) MX2008015253A (de)
PL (1) PL2037887T3 (de)
PT (1) PT2037887E (de)
RU (1) RU2446800C2 (de)
SI (1) SI2037887T1 (de)
WO (1) WO2007142951A2 (de)

Families Citing this family (13)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CZ298749B6 (cs) 1996-10-18 2008-01-16 Vertex Pharmaceuticals Incorporated Inhibitory serinových proteáz a farmaceutické prostředky s jejich obsahem
SV2003000617A (es) 2000-08-31 2003-01-13 Lilly Co Eli Inhibidores de la proteasa peptidomimetica ref. x-14912m
TW201127828A (en) 2003-09-05 2011-08-16 Vertex Pharma Inhibitors of serine proteases, particularly HCV NS3-NS4A protease
CN101277950B (zh) * 2005-08-02 2013-03-27 弗特克斯药品有限公司 丝氨酸蛋白酶抑制剂
US8399615B2 (en) 2005-08-19 2013-03-19 Vertex Pharmaceuticals Incorporated Processes and intermediates
US7964624B1 (en) 2005-08-26 2011-06-21 Vertex Pharmaceuticals Incorporated Inhibitors of serine proteases
AR055395A1 (es) * 2005-08-26 2007-08-22 Vertex Pharma Compuestos inhibidores de la actividad de la serina proteasa ns3-ns4a del virus de la hepatitis c
CA2643688A1 (en) 2006-02-27 2007-08-30 Vertex Pharmaceuticals Incorporated Co-crystals and pharmaceutical compositions comprising the same
US20070225297A1 (en) 2006-03-16 2007-09-27 Perni Robert B Deuterated hepatitis C protease inhibitors
EP2134717A2 (de) * 2007-02-27 2009-12-23 Vertex Pharmceuticals Incorporated Serinprotease-hemmer
MX2009009182A (es) * 2007-02-27 2009-09-04 Vertex Pharma Co-cristales y composiciones farmaceuticas que los comprenden.
NZ583699A (en) 2007-08-30 2012-04-27 Vertex Pharma Co-crystals of vx-950 (telaprevir) other components and pharmaceutical compositions comprising the same
CN111346060A (zh) * 2020-03-23 2020-06-30 山东达因海洋生物制药股份有限公司 一种释药速度可控的乙基纤维素掩味微球及其制备

Family Cites Families (12)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4439453A (en) * 1980-12-22 1984-03-27 Monsanto Company Directly compressible acetaminophen granulation
JPS6242918A (ja) * 1985-08-20 1987-02-24 Kaken Pharmaceut Co Ltd 持続性製剤
JPS6248618A (ja) * 1985-08-27 1987-03-03 Zeria Shinyaku Kogyo Kk 徐放性製剤およびその製造法
US4777050A (en) * 1987-03-23 1988-10-11 Schering Corporation Controlled-release dosage form comprising acetaminophen, pseudoephedrine and dexbrompheniramine
US5451409A (en) * 1993-11-22 1995-09-19 Rencher; William F. Sustained release matrix system using hydroxyethyl cellulose and hydroxypropyl cellulose polymer blends
GB9501127D0 (en) * 1995-01-20 1995-03-08 Wellcome Found Tablet
JPH1017497A (ja) * 1996-07-02 1998-01-20 Takeda Chem Ind Ltd 徐放性製剤およびその製造方法
UA74141C2 (uk) * 1998-12-09 2005-11-15 Дж.Д. Сірл Енд Ко. Фармацевтична композиція на основі тонкоподрібненого еплеренону (варіанти), спосіб її одержання та спосіб лікування розладів, опосередкованих альдостероном (варіанти)
PE20011350A1 (es) * 2000-05-19 2002-01-15 Vertex Pharma PROFARMACO DE UN INHIBIDOR DE ENZIMA CONVERTIDORA DE INTERLEUCINA-1ß (ICE)
JP2004517918A (ja) * 2000-10-18 2004-06-17 イミュネックス・コーポレーション Ｉｌ−１７アンタゴニストを使用する慢性関節リューマチの治療法
US6811794B2 (en) * 2001-12-20 2004-11-02 Shire Laboratories, Inc. Sustained release pharmaceutical dosage forms with minimized pH dependent dissolution profiles
MXPA06013256A (es) * 2004-05-15 2007-02-08 Vertex Pharma Tratamiento de crisis convulsivas utilizando inhibidores ice.

Also Published As

Publication number Publication date
US20110021598A1 (en) 2011-01-27
RU2008152085A (ru) 2010-07-10
CN101489530A (zh) 2009-07-22
WO2007142951A2 (en) 2007-12-13
IL195572A (en) 2012-08-30
DK2037887T3 (da) 2011-01-03
RU2446800C2 (ru) 2012-04-10
CY1111439T1 (el) 2015-08-05
ES2351947T3 (es) 2011-02-14
SI2037887T1 (sl) 2011-01-31
MX2008015253A (es) 2008-12-17
DE602007009230D1 (de) 2010-10-28
IL195572A0 (en) 2009-09-01
PL2037887T3 (pl) 2011-03-31
EP2037887B1 (de) 2010-09-15
US20080070972A1 (en) 2008-03-20
PT2037887E (pt) 2010-12-07
CA2653625A1 (en) 2007-12-13
WO2007142951A3 (en) 2008-03-06
KR20090018843A (ko) 2009-02-23
EP2037887A2 (de) 2009-03-25
JP2009538912A (ja) 2009-11-12
AU2007254990A1 (en) 2007-12-13

Similar Documents

Publication Publication Date Title
ATE481089T1 (de) Orale formulierungen mit kontrollierter freisetzung eines interleukin-1-beta-converting- enzyme inhibitors
ECSP099721A (es) Inhibidores de cinasa p70 s6
UY30320A1 (es) Formas polimorficas de 1-((4-metil-quinazolin-2-il)metil)--3-metil-7-(2-butin-1-il)-8-(3-(r)-amino-piperidin-1-il)-xantina, preparaciones, composiciones de preparacion y aplicaciones de las mismas.
CL2011002180A1 (es) Compuestos derivados de benzimidazol, inhibidores de mpges-1; composicion farmaceutica que los comprende; y su uso en el tratamiento de enfermedades inflamatorias y dolor.
CL2013000304A1 (es) Compuestos derivados de 2-arilamino-bencimidazoles inhibidores de prostaglandina e2 (mpges-1); composicion farmaceutica que los comprende; compuestos intermediarios; uso en el tratamiento de enfermedades inflamatorias y/o afecciones asociadas, en particular el dolor.
DK2695609T3 (da) Orale formuleringer af cytidinanaloger og fremgangsmåder til anvendelse deraf
MX377553B (es) Composicion farmaceutica estable y metodos de uso de la misma.
AR062000A1 (es) Formulaciones de modificador de respuesta inmune
EA201000775A1 (ru) Ингибиторы бета-лактамазы
EA201200049A1 (ru) 1,3-дизамещенные производные имидазолидин-2-она в качестве ингибиторов cyp 17
ECSP088800A (es) Formulaciones de inhibidores de DPP IV
MA33197B1 (fr) Inhibiteurs de tripeptide époxy cétone protéases cristallines
GEP20156242B (en) 2-arylimidazole derivatives as pde10a enzyme inhibitors
BR112012011328A2 (pt) inibidores de akt
EA201101118A1 (ru) Фармацевтические композиции, включающие производные 2-оксо-1-пирролидина
GT200900192A (es) Derivados de imidazol como inhibidores de proteina de uso de cinesina (eg-5).-
GT200800206A (es) Dimeros de derivados de artemisinina, su preparacion y su aplicacion en terapeutica
MX341431B (es) Producto de cuidado oral para el cuidado de esmalte sensible.
EP2040718A4 (de) Galliumnitrid-formulierungen
EP2044926A4 (de) Orale zusammensetzung für dentale zwecke
GT200600117A (es) Nuevos compuestos farmaceuticos
ECSP099561A (es) Formulación de nevirapina de liberación prolongada
DK3348258T3 (da) Orale og injicerbare formuleringer af tetracyclinforbindelser
PA8717801A1 (es) Formulaciones farmaceuticas de una forma cristalina de monohidrato de 2-(3-fluor-4-hidroxifenil)-7-vinil-1,3-benzoxazol-5-ol
PA8657801A1 (es) Aminalcoholes triciclicos, procedimientos para su preparacion

Legal Events

Date Code Title Description
UEP Publication of translation of european patent specification

Ref document number: 2037887

Country of ref document: EP